Genome-wide DNA methylation status is a predictor of the efficacy of anti-EGFR antibodies in the second-line treatment of metastatic colorectal cancer: Translational research of the EPIC trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

International Journal of Colorectal Disease

Topics

Medicine

Cancer Oncology

Internal Medicine

Pathology And Forensic Medicine

Cancer Research

Show all topics

DOI

10.1007/s00384-024-04659-y

License

CC-BY

Other Formats

PDF